A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
Completed · Phase 3 · NCT02963766
Conditions: Type 2 Diabetes
At a glance
- Research payments reported, 2025
- $3,196
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 154
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Dulaglutide (drug), Placebo (drug)
- Dates
- Started 2016-12-29; completion 2022-01-12
- Results posted
- Yes
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks.
From ClinicalTrials.gov, last updated 2022-07-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $3,196 in research payments for this study in 2025 (1 payments).
Products named: Trulicity
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.